Review of neonatal Fc receptor (FcRn) blockers, being developed by J&J, argenx & UCB, showing utility in autoimmune dz as they reduce autoantibodies. FcRn inhibitor market may be worth USD 3.3 billion by 2035. Approved for myasthenia gravis & being developed in Sjögren’s, SLE, https://t.co/mBUla87dK5